Florian Ingo Schmidt

Florian I. Schmidt studied Biochemistry at TU Munich with research stays in Hamburg, San Diego, Oxford, and New York. During his PhD at ETH Zurich, he investigated the entry of viruses into host cells. In 2013, Florian joined the Whitehead Institute at MIT to further develop the nanobody technology and apply it to better understand virus infections and innate immune responses. Since 2017, he is leading his own research group at the University of Bonn, where Paul-Albert Koenig and him set up a core facility for nanobody discovery. In 2020, both co-founded DiosCURE Therapeutics SE.